AN2 Therapeutics, Inc. (ANTX) vs Veraxa Biotech AG (VRXA)

AN2 Therapeutics, Inc. ANTX 4.00 +1.01%
Veraxa Biotech AG VRXA 0.95 0.00%

AN2 Therapeutics, Inc. and Veraxa Biotech AG are both Biotechnology companies. AN2 Therapeutics, Inc. and Veraxa Biotech AG are of similar size ($150.9M and $140.4M).

Metric	ANTX	VRXA	Biotechnology median
P/E	n/m	—	10.60
P/S	n/m	—	9.40
P/B	2.36	—	2.13
Price to free cash flow	n/m	—	25.18
EV/EBITDA	n/m	—	0.66
EV/Sales	n/m	—	9.02
Earnings yield	(26.75%)	—	(32.88%)
Free cash flow yield	(17.14%)	—	(23.13%)

Metric	ANTX	VRXA	Biotechnology median
Gross margin	0.00%	—	68.51%
Operating margin	0.00%	—	0.00%
Net margin	0.00%	—	0.00%
Free cash flow margin	0.00%	—	0.00%
Return on equity	(50.12%)	—	(51.96%)
Return on assets	(46.06%)	—	(46.06%)
Return on invested capital	0.00%	—	0.00%

Metric	ANTX	VRXA	Biotechnology median
Revenue growth (TTM)	—	—	6.76%
EPS growth (last fiscal year)	32.56%	—	29.88%
Revenue growth, 5-year CAGR	—	—	9.75%
Net income growth, 5-year CAGR	0.00%	—	0.00%

Metric	ANTX	VRXA	Biotechnology median
Debt to equity	0.00	—	0.00
Current ratio	14.32	—	4.97
Net debt to EBITDA	1.48	—	1.01

Metric	ANTX	VRXA	Biotechnology median
Dividend yield	—	—	0.41%
Payout ratio	—	—	—

Metric	ANTX	VRXA	Biotechnology median
Market cap	150.94m	140.35m	161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack